Stocks News

LAST PRICE
200.8400
TODAY'S CHANGE (%)
Trending Down-0.5900 (-0.2929%)

Bid / Lots
191.5100/ 1
Ask / Lots
208.6300/ 2
Open / Previous Close
202.3400 / 201.4300
Day Range
Low 200.3800
High 202.6600
52 Week Range
Low 187.6200
High 261.7300
Volume
513,705
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 26, 2024
- Goldman Sachs Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Buy Rating, from 7:10AM ET on Tuesday Nov 26, 2024 by MT Newswires
  7:10AM ET on Tuesday Nov 26, 2024 by MT Newswires
  Companies Mentioned: IQV
  07:10 AM EST, 11/26/2024 (MT Newswires) -- IQVIA Holdings (IQV) has an average rating of overweight and mean price target of $246.30, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major ba...
Nov 25, 2024
- Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $255 From $276, Maintains Buy Rating, from 5:56AM ET on Monday Nov 25, 2024 by MT Newswires
  5:56AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: IQV
  05:56 AM EST, 11/25/2024 (MT Newswires) -- IQVIA Holdings (IQV) has an average rating of overweight and mean price target of $247.30, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major ba...
- Baird Adjusts Price Target on IQVIA Holdings to $213 From $223, Maintains Neutral Rating, from 5:56AM ET on Monday Nov 25, 2024 by MT Newswires
  5:56AM ET on Monday Nov 25, 2024 by MT Newswires
  Companies Mentioned: IQV
  05:56 AM EST, 11/25/2024 (MT Newswires) -- IQVIA Holdings (IQV) has an average rating of overweight and mean price target of $247.30, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major ba...
Nov 19, 2024
- DJ IQVIA Holdings Price Target Cut to $248.00/Share From $260.00 by Leerink Partners, from 10:48AM ET on Tuesday Nov 19, 2024 by Dow Jones
  10:48AM ET on Tuesday Nov 19, 2024 by Dow Jones
  Companies Mentioned: IQV
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IQV/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 19, 2024 10:48 ET (15:48 GMT)
- Leerink Adjusts Price Target on IQVIA Holdings to $248 From $260, Maintains Outperform Rating, from 6:44AM ET on Tuesday Nov 19, 2024 by MT Newswires
  6:44AM ET on Tuesday Nov 19, 2024 by MT Newswires
  Companies Mentioned: IQV
  06:44 AM EST, 11/19/2024 (MT Newswires) -- IQVIA Holdings (IQV) has an average rating of overweight and mean price target of $248.85, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major ba...

Today
- Biogen, Eisai Launch Alzheimer's Drug Leqembi in South Korea, from 50 minutes ago by MT Newswires
  50 minutes ago by MT Newswires
  Companies Mentioned: BIIB
- Shareholder Rights Advocates at Levi & Korsinsky Investigate Regeneron Pharmaceuticals, Inc. (REGN) Regarding Possible Securities Fraud Violations, from 6 hours ago by Accesswire
  6 hours ago by Accesswire
  Companies Mentioned: REGN
- Shareholder Rights Advocates at Levi & Korsinsky Investigate Regeneron Pharmaceuticals, Inc. (REGN) Regarding Possible Securities Fraud Violations, from 6 hours ago by Dow Jones
  6 hours ago by Dow Jones
  Companies Mentioned: REGN
Nov 27, 2024
- "LEQEMBI(R)" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea, from 7:31PM ET on Wednesday Nov 27, 2024 by PR Newswire
  7:31PM ET on Wednesday Nov 27, 2024 by PR Newswire
  Companies Mentioned: BIIB
- "LEQEMBI(R)" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea, from 7:31PM ET on Wednesday Nov 27, 2024 by Dow Jones
  7:31PM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: BIIB
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 4:00PM ET on Wednesday Nov 27, 2024 by Dow Jones
  4:00PM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: REGN
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors, from 4:00PM ET on Wednesday Nov 27, 2024 by Dow Jones
  4:00PM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: ICLR
Nov 26, 2024
- ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights, from 1:01PM ET on Tuesday Nov 26, 2024 by Accesswire
  1:01PM ET on Tuesday Nov 26, 2024 by Accesswire
  Companies Mentioned: REGN
- ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights, from 1:01PM ET on Tuesday Nov 26, 2024 by Dow Jones
  1:01PM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: REGN
- INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones
  12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: REGN

IQVIA Holdings Inc
NYSE:IQVUnited States

Search Criteria

Nov 26, 2024

Goldman Sachs Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Buy Rating, from 7:10AM ET on Tuesday Nov 26, 2024 by MT Newswires

Nov 25, 2024

Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $255 From $276, Maintains Buy Rating, from 5:56AM ET on Monday Nov 25, 2024 by MT Newswires

Baird Adjusts Price Target on IQVIA Holdings to $213 From $223, Maintains Neutral Rating, from 5:56AM ET on Monday Nov 25, 2024 by MT Newswires

Nov 19, 2024

DJ IQVIA Holdings Price Target Cut to $248.00/Share From $260.00 by Leerink Partners, from 10:48AM ET on Tuesday Nov 19, 2024 by Dow Jones

Leerink Adjusts Price Target on IQVIA Holdings to $248 From $260, Maintains Outperform Rating, from 6:44AM ET on Tuesday Nov 19, 2024 by MT Newswires

Peers Headlines

Today

Biogen, Eisai Launch Alzheimer's Drug Leqembi in South Korea, from 50 minutes ago by MT Newswires

Shareholder Rights Advocates at Levi & Korsinsky Investigate Regeneron Pharmaceuticals, Inc. (REGN) Regarding Possible Securities Fraud Violations, from 6 hours ago by Accesswire

Shareholder Rights Advocates at Levi & Korsinsky Investigate Regeneron Pharmaceuticals, Inc. (REGN) Regarding Possible Securities Fraud Violations, from 6 hours ago by Dow Jones

Nov 27, 2024

"LEQEMBI(R)" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea, from 7:31PM ET on Wednesday Nov 27, 2024 by PR Newswire

"LEQEMBI(R)" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea, from 7:31PM ET on Wednesday Nov 27, 2024 by Dow Jones

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 4:00PM ET on Wednesday Nov 27, 2024 by Dow Jones

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ICON Public Limited Company (ICLR) on Behalf of Investors, from 4:00PM ET on Wednesday Nov 27, 2024 by Dow Jones

Nov 26, 2024

ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights, from 1:01PM ET on Tuesday Nov 26, 2024 by Accesswire

ATTENTION Regeneron Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights, from 1:01PM ET on Tuesday Nov 26, 2024 by Dow Jones

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors, from 12:00PM ET on Tuesday Nov 26, 2024 by Dow Jones